A Botox consent form is not a checkbox. It is the written record of a conversation in which a patient was told what the treatment involves, what it does not guarantee, what can go wrong, and what the alternatives are — before a needle touches their face. Done well, it protects both the patient and the provider. Done poorly, it is the document a malpractice attorney will focus on first.
This article is not a template. Templates are jurisdiction-specific, product-specific, and practice-specific — the American Society of Plastic Surgeons (ASPS), the American Society for Aesthetic Plastic Surgery (The Aesthetic Society), and the American Med Spa Association (AmSpa) all publish reference consent frameworks that should be adapted by a healthcare attorney for each practice. What this article covers is the substance: what informed consent for botulinum toxin requires, what the most common gaps are, and how practices and patients can recognize a form that does the job.
Why informed consent for neurotoxins is different from a generic procedure consent
Botulinum toxin type A products — Botox Cosmetic (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), and Letybo (letibotulinumtoxinA-wlbg) — carry an FDA Boxed Warning regarding the potential for distant spread of toxin effects beyond the injection site. The FDA also requires a Risk Evaluation and Mitigation Strategy (REMS) that includes a patient medication guide to be distributed with each product.
This is not a formality. The Boxed Warning and REMS mean that a neurotoxin consent form must address risks that go beyond the injection site — including dysphagia, breathing difficulties, and generalized muscle weakness that have been reported, predominantly in therapeutic (higher-dose) use but theoretically possible at cosmetic doses.
A consent form that lists "bruising and swelling" without mentioning the Boxed Warning is incomplete. A form that does not distinguish between FDA-approved indications and off-label treatment areas is also incomplete.
What every Botox consent form should cover
1. Procedure description and mechanism
The form should describe — in plain language — what botulinum toxin does: it temporarily blocks nerve signals to the injected muscles, reducing their ability to contract. It should state that the effect is temporary (typically 3–4 months for most products, with Daxxify potentially longer) and that results are not immediate (onset is typically 3–7 days for most products, up to 14 days for full effect).
2. Product identification
The specific product being used should be named, not just "Botox" used generically. Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo are not interchangeable — they have different molecular structures, unit dosing (Dysport units are not equivalent to Botox units), excipients (Botox contains albumin; Xeomin does not), and duration profiles. The consent form should reflect the actual product.
3. FDA-approved vs. off-label treatment areas
The form should distinguish between FDA-approved cosmetic indications and off-label use. As of 2026:
- Botox Cosmetic is FDA-approved for glabellar lines (frown lines between the eyebrows), lateral canthal lines (crow's feet), forehead lines, and — as of October 2024 — platysma bands (vertical neck bands).
- Dysport is FDA-approved for glabellar lines.
- Xeomin is FDA-approved for glabellar lines and, as of July 2024, for forehead lines and lateral canthal lines (crow's feet) — making it the first neurotoxin FDA-approved for the simultaneous treatment of all three upper facial areas.
- Jeuveau is FDA-approved for glabellar lines.
- Daxxify is FDA-approved for glabellar lines (September 2022) and cervical dystonia (August 2023).
- Letybo received FDA approval in February 2024 for glabellar lines.
Any treatment outside these approved areas — masseter reduction, brow lift, neck bands, "traptox" (trapezius slimming), excessive sweating (hyperhidrosis), migraine — is off-label. Off-label use is legal and common, but the consent form must disclose that the specific treatment area is not FDA-approved for the product being used. A patient who later experiences an adverse event from an off-label masseter injection deserves to know that the masseter was not an FDA-cleared treatment site.
4. Risks and potential complications
The consent form should address both common and serious risks. At minimum:
Common:
- Bruising, swelling, redness, and tenderness at injection sites
- Headache (reported in clinical trials)
- Temporary asymmetry or incomplete correction
- Flu-like symptoms
Serious (including Boxed Warning):
- Ptosis (drooping eyelid or brow) from migration of toxin
- Diplopia (double vision)
- Dysphagia (difficulty swallowing)
- Breathing difficulties
- Generalized muscle weakness
- Allergic reaction (including anaphylaxis), particularly in patients with sensitivity to albumin (present in some formulations) or latex (in some syringe components)
- Theoretical risk of distant toxin effects beyond the injection site
The ASPS informed consent template for botulinum toxin specifically addresses these risks and notes that patients with peripheral motor neuropathic disorders (amyotrophic lateral sclerosis, myasthenia gravis, Lambert-Eaton syndrome) may be at greater risk for clinically significant side effects.
5. Contraindications and precautions
The form should screen for:
- Pregnancy and breastfeeding (botulinum toxin is classified as FDA Pregnancy Category C; safety has not been established)
- Known hypersensitivity to botulinum toxin or any excipient (including albumin in some products)
- Neuromuscular disorders (myasthenia gravis, ALS, Lambert-Eaton syndrome)
- Active infection at the injection site
- Use of blood thinners (aspirin, warfarin, NSAIDs) — not a contraindication but a bruising risk that should be discussed
- Recent or planned cosmetic procedures in the same area
- Use of aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission
6. Expectations and limitations
The form should state clearly:
- Results are not guaranteed and vary by individual
- The effect is temporary and maintenance treatments are required
- Full effect may take up to 14 days to appear
- Touch-ups may be needed and may be charged separately (the practice's touch-up policy should be stated)
7. Alternatives
Informed consent requires disclosure of alternatives, including:
- No treatment
- Other neuromodulators (if the practice offers alternatives)
- Dermal fillers (for static lines not caused by muscle movement)
- Surgical options (for significant skin laxity or deep wrinkles)
- Topical treatments (retinoids, chemical peels)
8. Financial terms
The consent form should address:
- Cost per unit or per area, and how pricing is calculated
- Whether touch-ups are included or charged separately
- Cancellation and refund policies
- That cosmetic botulinum toxin is typically not covered by insurance
9. Post-treatment instructions
The form should reference or include post-treatment care: avoid rubbing the treated area, remain upright for several hours, avoid strenuous exercise for 24 hours, and follow any additional instructions provided by the injector.
10. Patient rights
The form should confirm that:
- The patient has had the opportunity to ask questions
- All questions have been answered to their satisfaction
- They understand they can decline or discontinue treatment at any time
- They consent to the specific treatment being described, not a blanket consent for future treatments
Common gaps that create liability
Based on consent form reviews from the Aesthetic Society's injectable safety workbook and malpractice case analysis from several aesthetic medicine legal sources:
Gap 1: Not distinguishing FDA-approved from off-label. If a form says "Botox for wrinkles" without specifying which wrinkles and whether the treatment area is approved, it fails to disclose a material fact.
Gap 2: Omitting the Boxed Warning. The FDA-required REMS medication guide should be offered to the patient. The consent form should reference the potential for distant spread of toxin effects.
Gap 3: Using the same form for multiple products. A "neurotoxin consent form" that names only Botox but is used when Dysport or Daxxify is administered is inaccurate. Each product has different excipients, unit conversions, and duration profiles.
Gap 4: No documentation of the informed consent conversation. A signed form without evidence that the provider actually discussed the contents is weaker than a form accompanied by a clinical note documenting the discussion. Best practice is both.
Gap 5: Expired consent forms. A consent form signed 12 months ago for a different treatment episode may not cover the current treatment, particularly if the patient's medical history, treatment areas, or the product used have changed. Many practices require a new consent for each treatment visit or at minimum annually.
Gap 6: Failure to document product lot number and units. The Aesthetic Society's injectable safety workbook recommends recording the specific product, lot number, expiration date, units injected, and anatomic areas treated. This is not optional documentation — it is the clinical record that supports the consent process.
State-specific considerations
Consent requirements vary by state. Key examples:
- Rhode Island's Medical Aesthetic Practices Safety Act (signed June 30, 2025, effective upon passage) requires informed consent before any medical aesthetic procedure, with specific disclosures about the provider's qualifications and the procedure's risks. The Department of Health is directed to promulgate implementing regulations by January 1, 2026.
- California requires that informed consent be obtained in a language the patient understands. If the patient's primary language is not English, translated forms or qualified interpreters should be available.
- New York requires written informed consent for cosmetic procedures. The state also has specific requirements for documentation and record retention.
- Texas requires that informed consent be documented for delegated procedures, including laser and injectable treatments performed under a medical director's supervision.
Regardless of state, the general legal standard is that a reasonable patient would want to know the information before making a treatment decision. If a risk is material — meaning it would change a reasonable patient's decision — it must be disclosed.
What patients should look for before signing
If you are a patient receiving botulinum toxin for the first time, you should expect to:
- Receive the consent form before the day of treatment — ideally at intake, so you can read it without time pressure. If you are handed a clipboard in the waiting room and told to "just sign this," that is not informed consent.
- See the specific product named. Not "Botox" as a generic term — the actual product and the fact that different products have different profiles.
- Be told whether your treatment areas are FDA-approved or off-label. Masseter Botox, "traptox," bunny lines, and neck bands are off-label. You should know that.
- Have the opportunity to ask questions and receive answers you understand. If the provider cannot explain a risk in plain language, that is a problem.
- Receive the FDA-required medication guide. The REMS for botulinum toxin products requires that patients be given the FDA medication guide. If you are not offered one, ask.
- See the provider document the lot number, units, and areas. This is your medical record. You have a right to know exactly what was injected, where, and how much.
Digital consent forms
Many practices have moved to digital consent platforms. These can improve legibility, ensure version control, and create timestamped records. However:
- The same substantive requirements apply. A digital form that omits the Boxed Warning is no better than a paper form that omits it.
- The patient must actually read the form. A platform that auto-scrolls to the signature line or makes the risk sections collapsible is not designed for genuine informed consent.
- HIPAA compliance is required. If the platform stores protected health information, it must meet HIPAA security standards. Generic form builders (Google Forms, Typeform) typically do not.
Sources
- U.S. FDA — Botox Cosmetic Prescribing Information (including Boxed Warning and REMS): https://www.accessdata.fda.gov/scripts/cder/daf/
- American Society of Plastic Surgeons — Informed Consent Template for Botulinum Toxin: https://www.plasticsurgery.org
- The Aesthetic Society — Injectables Safety Workbook (including sample consent forms): https://www.theaestheticsociety.org
- American Med Spa Association — Forms and Downloads (consent templates reviewed by ByrdAdatto attorneys): https://www.americanmedspa.org/forms-and-downloads
- Rhode Island Medical Aesthetic Practices Safety Act (SB 976 / HB 5351, 2025): https://webserver.rilegislature.gov/BillText25/HouseText25/H5351.pdf
- Empire Medical Training — What to Include in Botox Consent Forms: https://www.empiremedicaltraining.com/blog/what-to-include-in-botox-consent-forms
- APT Injection Training — The Botox Consent Form: What Every Injector Needs to Include: https://aptinjectiontraining.com/blog/the-botox-consent-form-what-every-injector-needs-to-include-before-treatment
